Accelerate to discover

Homepage>Discover>Genotype-targeted local therapy of glioma

Apr 4, 2024

Here, we assessed the chicken chorioallantoic membrane (CAM) as an alternative to mice for preclinical cancer imaging...

A microthrombus-driven fixed-point cleaved nanosystem for preventing post-thrombolysis recurrence

Apr 3, 2024

A thrombin-responsive and fixed-point cleaved Fu@pep-CLipo was developed for highly efficient and precise thrombolysis...

Webinar: Multimodal Assessment of Hypoxia in Tumors: From the Lab to the Clinic

Apr 2, 2024

25 April 2024, 4PM CET
This webinar will be of interest to multiple profiles in the community of biomedical
...

Multiplexed tissue imaging using the Orion platform to reveal the Spatial Biology of Cancer

Mar 27, 2024

In this webinar Prof. Sandro Santagata, will reveal how Orion high-plex imaging and the use of this data, is valuable...

Apr 26, 2024

A 19-color single-tube Full Spectrum Flow Cytometry for the detection of Acute Myeloid Leukemia

Mar 13, 2024

This recent publication in Cytometry Part A describes the development and comprehensive workflow of a single-tube,...

18F-labeled somatostatin analogs for somatostatin receptors (SSTRs) targeted PET imaging of NETs

Mar 11, 2024

A novel 18F-radiolabeled somatostatin analogue, [Al18F]NODA-MPAA-HTA, was synthesized and evaluated for positron...

Discover Yokogawa CellVoyager CQ1: Benchtop High-Content Analysis System

Mar 8, 2024

Unlike flow cytometers, the CellVoyager CQ1 confocal quantitative image cytometer does not require pretreatment such as...

Apr 26, 2024

Real-time and quantitative analysis of Macrophage Phagocytosis with RTCA eSight

Feb 23, 2024

The eSight is currently the only instrument that interrogates cell health and behavior using cellular
impedance
...

Show all topics (10)

Genotype-targeted local therapy of glioma

Mar 26, 2020

Aggressive neurosurgical resection to achieve sustained local control is essential for prolonging survival in patients with lower-grade glioma. However, progression in many of these patients is characterized by local regrowth. Most lower-grade gliomas harbor isocitrate dehydrogenase 1 (IDH1) or IDH2 mutations, which sensitize to metabolism-altering agents. To improve local control of IDH mutant gliomas while avoiding systemic toxicity associated with metabolic therapies, a precision intraoperative treatment was developer, that couples a rapid multiplexed genotyping tool with a sustained release microparticle (MP) drug delivery system containing an IDH-directed nicotinamide phosphoribosyltransferase (NAMPT) inhibitor (GMX-1778). GMX-1778 MPs showed mutant IDH genotype-specific toxicity in vitro and in vivo, inducing regression of orthotopic IDH mutant glioma murine models.

Do you want to learn more? Read the whole article!

Scientific paper

Application

Get more info